MAP2K7 and melanoma: Providing further support of this strategy, preclinical studies of ABT-737 in combination with a MEK inhibitor led to enhanced lethality, in vitro and in vivo utilizing BRAF-mutant melanoma cell lines and xenografts respectively, compared to either agent alone [39].